Symvivo Corporation is a Canadian biotechnology company based in Burnaby, British Columbia.
Activities
The COVID-19 Vaccine Task Force considered a proposal from Symvivo on June 22, 2020.[1]
Symvivo is developing an oral COVID-19 vaccine called bacTRL-Spike.[2]
The company has provided payments to numerous individuals involved in Canada's response to the declared COVID-19 pandemic, including Soren Gantt[3] and Manish Sadarangani.[4]
External links
COVID-19 Vaccine Task Force Registry of Interests. (2023, March 27). Innovation, Science and Economic Development Canada. http://archive.today/2023.07.09-180656/https://ised-isde.canada.ca/site/biomanufacturing/en/covid-19-vaccine-task-force/covid-19-vaccine-task-force-registry-interests ↩︎
Symvivo receives funding for COVID-19 vaccine program. (2021, July 19). Symvivo Corporation. https://web.archive.org/web/20220417182902/https://www.symvivo.com/media-2/symvivo-corporation-receives-funding-for-covid-19-vaccine-program ↩︎
Abu-Raya, B., Gantt, S., & Sadarangani, M. (2020). Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic. Canadian Medical Association Journal, 192(34), E982–E985. https://doi.org/10.1503/cmaj.201237 ↩︎
Evans, T., Sadarangani, M., Maguire, J., Zinszer, K., & Kellner, J. (2022). The importance of pediatric vaccination. COVID-19 Immunity Task Force. https://web.archive.org/web/20220424080020/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/03/CITF_CanCOVID_6_Pediatric-vaccination_2022_EN_FINAL-2.pdf ↩︎
